Study of NXP900 plus osimertinib for EGFR lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lung cancer called EGFR-mutated non-small cell lung cancer that has spread or cannot be removed with surgery.
- You have already been treated with the targeted therapy osimertinib (Tagrisso), either alone or with chemotherapy.
- You are 18 years or older and able to provide written consent.
- You are in good enough physical condition to be up and about (ECOG score of 0 or 1).
- You do not have other gene changes (like ALK, ROS1) that drive your cancer, and you do not have resistance to osimertinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This study tests a new drug (SYS6010) combined with an existing targeted therapy (osimertinib) for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than standard treatments and to find a safe dose.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
This trial tests if taking osimertinib before surgery can help treat a type of non-small cell lung cancer that has specific EGFR mutations. It aims to understand how the cancer may become resistant to this targeted therapy.
Hear when a new EGFR Mutation Positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.